Phase I clinical investigations of [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in breast cancer patients showed that both radiopharmaceuticals were well-tolerated in humans and discriminated HER2-positive and HER2-negative tumours [9,10]. This evidence concerns the gene ERBB2 and breast carcinoma.